Christina Lampe-Onnerud has found it much easier to get a foot in the door with partners and potential customers for her second lithium-ion battery startup, Cadenza Innovation, than for her first, Boston-Power.
Maybe that’s because the advanced battery market has matured... Read more »
Quarterly biopharma earnings added a little heat to the already high summer temperatures. Amongst several companies to report this week, the biggest news came from Gilead Sciences (NASDAQ: GILD), whose hepatitis C drugs have become some of the top revenue... Read more »
Seres Therapeutics raised $134 million in an IPO and made history in the process, becoming the first drug developer targeting the microbiome to go public in the U.S. But disappointing news from the Cambridge, MA, company today shows just how much... Read more »
The big drug news from the annual Alzheimer’s Association meeting this week involved companies that have found silver linings in otherwise gloomy data—a recurrent theme in Alzheimer’s clinical work. The trials are expensive, so companies are loathe to write them off... Read more »
[Corrected 7/28/16 9:59 pm. See below.] Joy Tang knows models—both the algorithmic ones she helped develop while working in high-frequency stock trading for six years, and the human ones who grace magazine pages and strut along runways at fashion... Read more »
In 2015, Silicon Valley venture firm founder Robert Ackerman was helping the founders of Maryland startup Onyara to prepare for a fundraising round that would allow them to mine the commercial potential of advanced data processing technology developed at the National... Read more »
Lawn Guru, an app that allows users to connect with lawn care professionals and order services on demand, announced this week that it has closed a $1 million seed round. The round was led by Sierra Wasach Capital with participation from... Read more »
This week’s World Federation of Hemophilia World Congress in Orlando, FL, where researchers gathered to present the latest updates in treatments for the chronic bleeding disorder, marked the latest step in a journey that dates back more than two decades for... Read more »
An effective treatment for Prader-Willi Syndrome would mean more to Kate Kane than just being free of the insatiable hunger the disease causes. It could mean being able to do something as normal as hold a job—like her dream of being... Read more »
It took longer than FluGen planned, but a human clinical trial is now underway for the experimental universal influenza vaccine that the Madison, WI-based biotech startup is developing.
The primary goals of the trial announced Wednesday are to evaluate the safety... Read more »
A lot of California tech companies have gobbled up Boston-area firms over the years, often leaving local advocates lamenting the loss of yet another headquarters or anchor tech company.
On Tuesday it was the reverse.
Boston-based LogMeIn (NASDAQ: LOGM) announced plans... Read more »
[Updated, 2:30 p.m. ET, see below] It’s not uncommon for a biotech’s larger partner to make a buyout offer for its smaller counterpart. But unfortunately for Bind Therapeutics, that bid, from pharma giant Pfizer, means the company could be... Read more »
LabCorp, already a giant in diagnostics and laboratory testing, is building its capabilities in prenatal testing with an agreement to acquire Sequenom in a $371 million deal.
Under the tender offer, Burlington, NC-based LabCorp (NYSE: LH) will acquire all of... Read more »